Viridian Therapeutics (VRDN) Stock Forecast, Price Target & Predictions
VRDN Stock Forecast
Viridian Therapeutics stock forecast is as follows: an average price target of $37.83 (represents a 71.49% upside from VRDN’s last price of $22.06) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
VRDN Price Target
The average price target for Viridian Therapeutics (VRDN) is $37.83 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $56.00 to $22.00. This represents a potential 71.49% upside from VRDN's last price of $22.06.
VRDN Analyst Ratings
According to 11 Wall Street analysts, Viridian Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VRDN stock is 0 'Strong Buy' (0.00%), 10 'Buy' (90.91%), 1 'Hold' (9.09%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Viridian Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | Gregory Renza | RBC Capital | $44.00 | $20.70 | 112.56% | 99.46% |
| Sep 11, 2024 | Serge Belanger | Needham | $38.00 | $19.02 | 99.79% | 72.26% |
| Sep 11, 2024 | Kalpit Patel | B.Riley Financial | $22.00 | $19.24 | 14.35% | -0.27% |
| Sep 10, 2024 | Alex Thompson | Stifel Nicolaus | $40.00 | $17.36 | 130.35% | 81.32% |
| Sep 10, 2024 | Julian Harrison | BTIG | $56.00 | $17.27 | 224.26% | 153.85% |
| Aug 14, 2024 | Richard Law | Goldman Sachs | $25.00 | $14.18 | 76.30% | 13.33% |
| Jun 11, 2024 | Gregory Renza | RBC Capital | $35.00 | $12.96 | 170.01% | 58.66% |
| Jun 11, 2024 | Julian Harrison | BTIG | $46.00 | $12.96 | 254.94% | 108.52% |
| Jun 10, 2024 | Andy Chen | Wolfe Research | $29.00 | $12.22 | 137.32% | 31.46% |
| Jun 06, 2024 | Richard Law | Goldman Sachs | $23.00 | $12.34 | 86.39% | 4.26% |
The latest Viridian Therapeutics stock forecast, released on Sep 13, 2024 by Gregory Renza from RBC Capital, set a price target of $44.00, which represents a 112.56% increase from the stock price at the time of the forecast ($20.70), and a 99.46% increase from VRDN last price ($22.06).
Viridian Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 5 | 6 | 13 |
| Avg Price Target | $40.00 | $37.50 | $33.54 |
| Last Closing Price | $22.06 | $22.06 | $22.06 |
| Upside/Downside | 81.32% | 69.99% | 52.04% |
In the current month, the average price target of Viridian Therapeutics stock is $40.00, according to 5 Wall Street analysts offering twelve months forecast. The average price target represents a 81.32% increase as opposed to Viridian Therapeutics's last price of $22.06. This month's average price target is up 6.67% compared to last quarter, and up 19.26% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Sep 11, 2024 | Needham | Buy | Buy | Hold |
| Sep 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 10, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Sep 10, 2024 | Wedbush | Buy | Buy | Hold |
| Sep 10, 2024 | BTIG | Buy | Buy | Hold |
| Aug 15, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 15, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Aug 14, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jul 16, 2024 | Oppenheimer | Buy | Buy | Hold |
Viridian Therapeutics's last stock rating was published by RBC Capital on Sep 13, 2024. The company gave VRDN a "Outperform" rating, the same as its previous rate.
Viridian Therapeutics Financial Forecast
Viridian Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $72.00K | $72.00K | $98.00K | $105.00K | $1.20M | - | $216.00K | $214.00K | $208.00K | $1.09M | $1.45M | $54.00K | - | $168.00K | $828.00K | $880.00K | $695.00K | $2.51M | $372.00K |
| Avg Forecast | $116.67K | $116.67K | $75.00K | $75.00K | $87.08K | $91.00K | $78.15K | $88.10K | $154.18K | $145.25K | $254.00K | $116.78K | $457.60K | $303.33K | $270.33K | $253.50K | $342.80K | $454.20K | $762.88K | $2.39M | $80.00K | $206.00K | $645.25K | $582.50K | $728.50K | $1.25M | $372.00K | $663.00K |
| High Forecast | $116.67K | $116.67K | $75.00K | $75.00K | $87.08K | $113.75K | $78.15K | $88.10K | $171.31K | $145.25K | $254.00K | $116.78K | $457.60K | $303.33K | $270.33K | $281.67K | $380.89K | $504.67K | $915.46K | $2.87M | $88.89K | $228.89K | $716.94K | $647.22K | $809.44K | $1.39M | $413.33K | $736.67K |
| Low Forecast | $116.67K | $116.67K | $75.00K | $75.00K | $87.08K | $79.63K | $78.15K | $88.10K | $119.92K | $145.25K | $254.00K | $116.78K | $457.60K | $303.33K | $270.33K | $225.33K | $304.71K | $403.73K | $610.31K | $1.91M | $71.11K | $183.11K | $573.55K | $517.78K | $647.55K | $1.11M | $330.67K | $589.33K |
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 8 | 6 | 5 | 11 | 12 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.50% | 0.28% | 0.84% | 0.23% | 3.94% | - | 0.85% | 0.62% | 0.46% | 1.43% | 0.61% | 0.68% | - | 0.26% | 1.42% | 1.21% | 0.55% | 6.76% | 0.56% |
Viridian Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $154.18K, with a low forecast of $119.92K, and a high forecast of $171.31K. VRDN's average Quarter revenue forecast represents a 114.14% increase compared to the company's last Quarter revenue of $72.00K (Sep 23).
Viridian Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 8 | 6 | 5 | 11 | 12 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-51.22M | $-59.27M | $-67.99M | $-45.62M | $-28.68M | - | $-25.85M | $-28.91M | $-14.01M | $-17.94M | $-18.43M | $-90.51M | $-5.34M | $-6.28M | $-7.83M | $-9.88M | $-10.96M | $-8.60M | $-11.32M |
| Avg Forecast | $-116.67K | $-116.67K | $-75.00K | $-75.00K | $-87.08K | $-91.00K | $-78.15K | $-88.10K | $-154.18K | $-145.25K | $-254.00K | $-116.78K | $-457.60K | $-303.33K | $-270.33K | $-253.50K | $-342.80K | $-13.31M | $-10.25M | $-30.33M | $-80.00K | $-206.00K | $-645.25K | $-582.50K | $-728.50K | $-1.25M | $-372.00K | $-663.00K |
| High Forecast | $-116.67K | $-116.67K | $-75.00K | $-75.00K | $-87.08K | $-79.63K | $-78.15K | $-88.10K | $-119.92K | $-145.25K | $-254.00K | $-116.78K | $-457.60K | $-303.33K | $-270.33K | $-225.33K | $-304.71K | $-10.65M | $-8.20M | $-24.27M | $-71.11K | $-183.11K | $-573.55K | $-517.78K | $-647.55K | $-1.11M | $-330.67K | $-589.33K |
| Low Forecast | $-116.67K | $-116.67K | $-75.00K | $-75.00K | $-87.08K | $-113.75K | $-78.15K | $-88.10K | $-171.31K | $-145.25K | $-254.00K | $-116.78K | $-457.60K | $-303.33K | $-270.33K | $-281.67K | $-380.89K | $-15.97M | $-12.30M | $-36.40M | $-88.89K | $-228.89K | $-716.94K | $-647.22K | $-809.44K | $-1.39M | $-413.33K | $-736.67K |
| Surprise % | - | - | - | - | - | - | - | - | - | 352.66% | 233.37% | 582.18% | 99.69% | 94.55% | - | 101.97% | 84.34% | 1.05% | 1.75% | 0.61% | 1131.40% | 25.94% | 9.73% | 13.45% | 13.56% | 8.74% | 23.11% | 17.08% |
undefined analysts predict VRDN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Viridian Therapeutics's previous annual EBITDA (undefined) of $NaN.
Viridian Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 8 | 6 | 5 | 11 | 12 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | $-47.66M | $-55.06M | $-68.05M | $-42.50M | $-28.02M | - | $-25.50M | $-28.95M | $-14.04M | $-17.96M | $-18.46M | $-90.74M | $-5.49M | $-6.43M | $-8.04M | $-10.12M | $-11.23M | $-8.90M | $-11.63M |
| Avg Forecast | $-63.54M | $-63.69M | $-62.32M | $-60.79M | $-65.63M | $-67.50M | $-55.60M | $-69.54M | $-62.44M | $-79.52M | $-80.50M | $-64.53M | $-46.51M | $-62.76M | $-54.81M | $-48.44M | $-41.52M | $-13.33M | $-10.26M | $-30.39M | $-84.29M | $-98.74M | $-122.96M | $-143.08M | $-187.80M | $-220.59M | $-277.60M | $-262.69M |
| High Forecast | $-63.54M | $-63.69M | $-62.32M | $-60.79M | $-65.63M | $-57.59M | $-55.60M | $-69.54M | $-50.88M | $-79.52M | $-80.50M | $-64.53M | $-46.51M | $-62.76M | $-54.81M | $-41.44M | $-35.52M | $-10.67M | $-8.21M | $-24.31M | $-72.12M | $-84.48M | $-105.20M | $-122.42M | $-160.67M | $-188.72M | $-237.50M | $-224.75M |
| Low Forecast | $-63.54M | $-63.69M | $-62.32M | $-60.79M | $-65.63M | $-72.46M | $-55.60M | $-69.54M | $-80.36M | $-79.52M | $-80.50M | $-64.53M | $-46.51M | $-62.76M | $-54.81M | $-55.44M | $-47.52M | $-16.00M | $-12.31M | $-36.46M | $-96.47M | $-113.01M | $-140.72M | $-163.75M | $-214.92M | $-252.45M | $-317.69M | $-300.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.60% | 0.68% | 1.05% | 0.91% | 0.45% | - | 0.53% | 0.70% | 1.05% | 1.75% | 0.61% | 1.08% | 0.06% | 0.05% | 0.06% | 0.05% | 0.05% | 0.03% | 0.04% |
Viridian Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRDN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Viridian Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 8 | 6 | 5 | 11 | 12 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | $20.91M | $19.26M | $21.83M | $9.85M | $8.86M | - | $8.36M | $6.90M | $6.22M | $6.52M | $6.16M | $5.54M | $2.30M | $2.71M | $2.72M | $2.53M | $2.90M | $2.86M | $3.36M |
| Avg Forecast | $8.08M | $8.08M | $5.20M | $5.20M | $6.03M | $6.30M | $5.41M | $6.10M | $10.68M | $10.06M | $17.59M | $8.09M | $31.70M | $21.01M | $18.73M | $17.56M | $23.75M | $31.46M | $52.85M | $165.45M | $5.54M | $14.27M | $44.70M | $40.35M | $50.46M | $86.83M | $25.77M | $45.93M |
| High Forecast | $8.08M | $8.08M | $5.20M | $5.20M | $6.03M | $7.88M | $5.41M | $6.10M | $11.87M | $10.06M | $17.59M | $8.09M | $31.70M | $21.01M | $18.73M | $19.51M | $26.38M | $34.96M | $63.41M | $198.54M | $6.16M | $15.86M | $49.66M | $44.83M | $56.07M | $96.48M | $28.63M | $51.03M |
| Low Forecast | $8.08M | $8.08M | $5.20M | $5.20M | $6.03M | $5.52M | $5.41M | $6.10M | $8.31M | $10.06M | $17.59M | $8.09M | $31.70M | $21.01M | $18.73M | $15.61M | $21.11M | $27.97M | $42.28M | $132.36M | $4.93M | $12.68M | $39.73M | $35.87M | $44.86M | $77.18M | $22.91M | $40.82M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.08% | 1.09% | 2.70% | 0.31% | 0.42% | - | 0.48% | 0.29% | 0.20% | 0.12% | 0.04% | 1.00% | 0.16% | 0.06% | 0.07% | 0.05% | 0.03% | 0.11% | 0.07% |
Viridian Therapeutics's average Quarter SG&A projection for Dec 23 is $10.68M, based on 6 Wall Street analysts, with a range of $8.31M to $11.87M. The forecast indicates a -48.93% fall compared to VRDN last annual SG&A of $20.91M (Sep 23).
Viridian Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 8 | 6 | 5 | 11 | 12 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.09 | $-0.00 | $-1.61 | $-1.05 | $-0.83 | - | $-0.98 | $-2.59 | $-1.25 | $-2.21 | $-2.91 | $-23.07 | $-1.50 | $-1.80 | $-2.70 | $-4.65 | $-5.40 | $-4.35 | $-5.70 |
| Avg Forecast | $-0.99 | $-1.00 | $-0.98 | $-0.95 | $-1.03 | $-1.06 | $-0.87 | $-1.09 | $-0.98 | $-1.25 | $-1.26 | $-1.01 | $-0.73 | $-0.98 | $-0.90 | $-0.97 | $-0.84 | $-1.25 | $-1.36 | $-0.76 | $-1.70 | $-1.99 | $-2.48 | $-2.88 | $-3.78 | $-4.44 | $-5.59 | $-5.29 |
| High Forecast | $-0.99 | $-1.00 | $-0.98 | $-0.95 | $-1.03 | $-0.90 | $-0.87 | $-1.09 | $-0.80 | $-1.25 | $-1.26 | $-1.01 | $-0.73 | $-0.98 | $-0.90 | $-0.83 | $-0.71 | $-1.07 | $-1.17 | $-0.65 | $-1.45 | $-1.70 | $-2.12 | $-2.46 | $-3.23 | $-3.80 | $-4.78 | $-4.52 |
| Low Forecast | $-0.99 | $-1.00 | $-0.98 | $-0.95 | $-1.03 | $-1.13 | $-0.87 | $-1.09 | $-1.26 | $-1.25 | $-1.26 | $-1.01 | $-0.73 | $-0.98 | $-0.90 | $-1.12 | $-0.96 | $-1.43 | $-1.56 | $-0.87 | $-1.94 | $-2.27 | $-2.83 | $-3.30 | $-4.33 | $-5.08 | $-6.39 | $-6.05 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.88% | 0.00% | 1.59% | 1.44% | 0.84% | - | 1.01% | 3.10% | 1.00% | 1.62% | 3.85% | 13.60% | 0.75% | 0.73% | 0.94% | 1.23% | 1.22% | 0.78% | 1.08% |
According to undefined Wall Street analysts, Viridian Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRDN previous annual EPS of $NaN (undefined).
Viridian Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ETNB | 89bio | $8.48 | $22.00 | 159.43% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
VRDN Forecast FAQ
Is Viridian Therapeutics a good buy?
Yes, according to 11 Wall Street analysts, Viridian Therapeutics (VRDN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 90.91% of VRDN's total ratings.
What is VRDN's price target?
Viridian Therapeutics (VRDN) average price target is $37.83 with a range of $22 to $56, implying a 71.49% from its last price of $22.06. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Viridian Therapeutics stock go up soon?
According to Wall Street analysts' prediction for VRDN stock, the company can go up by 71.49% (from the last price of $22.06 to the average price target of $37.83), up by 153.85% based on the highest stock price target, and down by -0.27% based on the lowest stock price target.
Can Viridian Therapeutics stock reach $30?
VRDN's average twelve months analyst stock price target of $37.83 supports the claim that Viridian Therapeutics can reach $30 in the near future.
What is Viridian Therapeutics's current price target trend?
5 Wall Street analysts forecast a $40 price target for Viridian Therapeutics (VRDN) this month, up 81.32% from its last price of $22.06. Compared to the last 3 and 12 months, the average price target increased by 69.99% and increased by 52.04%, respectively.
What are Viridian Therapeutics's analysts' financial forecasts?
Viridian Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $344.34K (high $367.09K, low $332.96K), average EBITDA is $-344K (high $-333K, low $-367K), average net income is $-258M (high $-248M, low $-263M), average SG&A $23.85M (high $25.43M, low $23.06M), and average EPS is $-4.045 (high $-3.89, low $-4.122). VRDN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $383.33K (high $383.33K, low $383.33K), average EBITDA is $-383K (high $-383K, low $-383K), average net income is $-250M (high $-250M, low $-250M), average SG&A $26.55M (high $26.55M, low $26.55M), and average EPS is $-3.921 (high $-3.921, low $-3.921).
Did the VRDN's actual financial results beat the analysts' financial forecasts?
Based on Viridian Therapeutics's last annual report (Dec 2023), the company's revenue was $314K, which missed the average analysts forecast of $670.21K by -53.15%. Apple's EBITDA was $-254M, beating the average prediction of $-670K by 37865.71%. The company's net income was $-238M, missing the average estimation of $-287M by -17.16%. Apple's SG&A was $95M, beating the average forecast of $46.43M by 104.63%. Lastly, the company's EPS was $-0.0053, missing the average prediction of $-4.494 by -99.88%. In terms of the last quarterly report (Sep 2023), Viridian Therapeutics's revenue was $72K, missing the average analysts' forecast of $145.25K by -50.43%. The company's EBITDA was $-51.224M, beating the average prediction of $-145K by 35166.09%. Viridian Therapeutics's net income was $-47.66M, missing the average estimation of $-79.524M by -40.07%. The company's SG&A was $20.91M, beating the average forecast of $10.06M by 107.83%. Lastly, the company's EPS was $-1.09, missing the average prediction of $-1.245 by -12.48%